Mucosal adenovirus-vectored vaccine for measles

Vaccine

Volumn 28, Issue 48, 2010, Pages 7613-7619

  Lobanova, Liubov M ^a,b   aig, Tayyba T ^a   Tikoo, Suresh K ^a,b   Zakhartchouk, Alexander N ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Adenovirus; Measles; Mucosal vaccination

Indexed keywords

ADENOVIRUS VECTOR; ANTIBODY; IMMUNOGLOBULIN A; MEASLES VACCINE; NEUTRALIZING ANTIBODY; VIRUS FUSION PROTEIN; VIRUS HEMAGGLUTININ;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN ADENOVIRUS; HUMAN CELL; IMMUNE RESPONSE; LUNG LAVAGE; MALE; MEASLES; MEASLES VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; VIRUS LOAD;

ADENOVIRIDAE; ADMINISTRATION, INTRANASAL; ADMINISTRATION, MUCOSAL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; FEMALE; GENETIC VECTORS; HEK293 CELLS; HEMAGGLUTININS, VIRAL; HUMANS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; INJECTIONS, INTRAMUSCULAR; LUNG; MEASLES; MEASLES VACCINE; MEASLES VIRUS; MICE; MICE, INBRED C57BL; NEUTRALIZATION TESTS; RATS; VERO CELLS; VIRAL FUSION PROTEINS;

EID: 78249259370     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.09.055     Document Type: Article

References (40)

1. Griffin D.E. Measles virus 2001, Lippincott Williams & Wilkins, Philadelphia. 4th ed.
2. Global measles mortality, 2000-2008. Morb Mortal Wkly Rep 2009, 58(December (47)):1321-1326.
3. Angel J.B., Walpita P., Lerch R.A., Sidhu M.S., Masurekar M., DeLellis R.A., et al. Vaccine-associated measles pneumonitis in an adult with AIDS. Ann Intern Med 1998, 129(July (2)):104-106.
4. Putz M.M., Bouche F.B., de Swart R.L., Muller C.P. Experimental vaccines against measles in a world of changing epidemiology. Int J Parasitol 2003, 33(May (5-6)):525-545.
5. Gans H.A., Arvin A.M., Galinus J., Logan L., DeHovitz R., Maldonado Y. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA 1998, 280(August (6)):527-532.
6. de Vries R.D., Stittelaar K.J., Osterhaus A.D., de Swart R.L. Measles vaccination: new strategies and formulations. Expert Rev Vaccines 2008, 7(October (8)):1215-1223.
7. de Swart R.L., Yuksel S., Osterhaus A.D. Relative contributions of measles virus hemagglutinin- and fusion protein-specific serum antibodies to virus neutralization. J Virol 2005, 79(September (17)):11547-11551.
8. Giraudon P., Wild T.F. Correlation between epitopes on hemagglutinin of measles virus and biological activities: passive protection by monoclonal antibodies is related to their hemagglutination inhibiting activity. Virology 1985, 144(July (1)):46-58.
9. Malvoisin E., Wild F. Contribution of measles virus fusion protein in protective immunity: anti-F monoclonal antibodies neutralize virus infectivity and protect mice against challenge. J Virol 1990, 64(October (10)):5160-5162.
10. Pan C.H., Greer C.E., Hauer D., Legg H.S., Lee E.Y., Bergen M.J., et al. A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles. J Virol 2010, 84(April (8)):3798-3807.
11. Pan C.H., Jimenez G.S., Nair N., Wei Q., Adams R.J., Polack F.P., et al. Use of Vaxfectin adjuvant with DNA vaccine encoding the measles virus hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques against measles virus. Clin Vaccine Immunol 2008, 15(August (8)):1214-1221.
12. Pasetti M.F., Ramirez K., Resendiz-Albor A., Ulmer J., Barry E.M., Levine M.M. Sindbis virus-based measles DNA vaccines protect cotton rats against respiratory measles: relevance of antibodies, mucosal and systemic antibody-secreting cells, memory B cells, and Th1-type cytokines as correlates of immunity. J Virol 2009, 83(March (6)):2789-2794.
13. van Binnendijk R.S., Poelen M.C., van Amerongen G., de Vries P., Osterhaus A.D. Protective immunity in macaques vaccinated with live attenuated, recombinant, and subunit measles vaccines in the presence of passively acquired antibodies. J Infect Dis 1997, 175(March (3)):524-532.
14. Polack F.P., Lee S.H., Permar S., Manyara E., Nousari H.G., Jeng Y., et al. Successful DNA immunization against measles: neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles. Nat Med 2000, 6(July (7)):776-781.
15. Alkhatib G., Briedis D.J. High-level eukaryotic in vivo expression of biologically active measles virus hemagglutinin by using an adenovirus type 5 helper-free vector system. J Virol 1988, 62(August (8)):2718-2727.
16. Alkhatib G., Richardson C., Shen S.H. Intracellular processing, glycosylation, and cell-surface expression of the measles virus fusion protein (F) encoded by a recombinant adenovirus. Virology 1990, 175(March (1)):262-270.
17. Fooks A.R., Jeevarajah D., Lee J., Warnes A., Niewiesk S., ter Meulen V., et al. Oral or parenteral administration of replication-deficient adenoviruses expressing the measles virus haemagglutinin and fusion proteins: protective immune responses in rodents. J Gen Virol 1998, 79(May (Pt 5)):1027-1031.
18. Top F.H., Grossman R.A., Bartelloni P.J., Segal H.E., Dudding B.A., Russell P.K., et al. Immunization with live types 7 and 4 adenovirus vaccines. I. Safety, infectivity, antigenicity, and potency of adenovirus type 7 vaccine in humans. J Infect Dis 1971, 124(August (2)):148-154.
19. Lewis J.A., Brown E.L., Duncan P.A. Approaches to the release of a master cell bank of PER. C6 cells; a novel cell substrate for the manufacture of human vaccines. Dev Biol (Basel) 2006, 123:165-176. discussion 83-97.
20. Evans R.K., Nawrocki D.K., Isopi L.A., Williams D.M., Casimiro D.R., Chin S., et al. Development of stable liquid formulations for adenovirus-based vaccines. J Pharm Sci 2004, 93(October (10)):2458-2475.
21. Lasaro M.O., Ertl H.C. New insights on adenovirus as vaccine vectors. Mol Ther 2009, 17(August (8)):1333-1339.
22. Xiang Z.Q., Yang Y., Wilson J.M., Ertl H.C. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology 1996, 219(May (1)):220-227.
23. McElrath M.J., De Rosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., et al. HIV-1 vaccine-induced immunity in the test-of-concept step study: a case-cohort analysis. Lancet 2008, 372(November (9653)):1894-1905.
24. Van Kampen K.R., Shi Z., Gao P., Zhang J., Foster K.W., Chen D.T., et al. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 2005, 23(January (8)):1029-1036.
25. Muhlebach M.D., Leonard V.H., Cattaneo R. The measles virus fusion protein transmembrane region modulates availability of an active glycoprotein complex and fusion efficiency. J Virol 2008, 82(November (22)):11437-11445.
26. Zakhartchouk A.N., Viswanathan S., Mahony J.B., Gauldie J., Babiuk L.A. Severe acute respiratory syndrome coronavirus nucleocapsid protein expressed by an adenovirus vector is phosphorylated and immunogenic in mice. J Gen Virol 2005, 86(January (Pt 1)):211-215.
27. Reed L.J., Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938, 27:493-497.
28. Nakayama T., Mori T., Yamaguchi S., Sonoda S., Asamura S., Yamashita R., et al. Detection of measles virus genome directly from clinical samples by reverse transcriptase-polymerase chain reaction and genetic variability. Virus Res 1995, 35(January (1)):1-16.
29. Wyde P.R., Stittelaar K.J., Osterhaus A.D., Guzman E., Gilbert B.E. Use of cotton rats for preclinical evaluation of measles vaccines. Vaccine 2000, 19(August (1)):42-53.
30. Moss W.J., Griffin D.E. Global measles elimination. Nat Rev Microbiol 2006, 4(December (12)):900-908.
31. Nair N., Gans H., Lew-Yasukawa L., Long-Wagar A.C., Arvin A., Griffin D.E. Age-dependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life. J Infect Dis 2007, 196(November (9)):1339-1345.
32. Polack F.P., Hoffman S.J., Moss W.J., Griffin D.E. Altered synthesis of interleukin-12 and type 1 and type 2 cytokinesin rhesus macaques during measles and atypical measles. J Infect Dis 2002, 185(January (1)):13-19.
33. Croyle M.A., Patel A., Tran K.N., Gray M., Zhang Y., Strong J.E., et al. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One 2008, 3(10):e3548.
34. Zakhartchouk A.N., Pyne C., Mutwiri G.K., Papp Z., Baca-Estrada M.E., Griebel P., et al. Mucosal immunization of calves with recombinant bovine adenovirus-3: induction of protective immunity to bovine herpesvirus-1. J Gen Virol 1999, 80(May (Pt 5)):1263-1269.
35. Niewiesk S. Current animal models: cotton rat animal model. Curr Top Microbiol Immunol 2009, 330:89-110.
36. Wang J., Thorson L., Stokes R.W., Santosuosso M., Huygen K., Zganiacz A., et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol 2004, 173(November (10)):6357-6365.
37. Thorner A.R., Vogels R., Kaspers J., Weverling G.J., Holterman L., Lemckert A.A., et al. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa. J Clin Microbiol 2006, 44(October (10)):3781-3783.
38. Vogels R., Zuijdgeest D., van Rijnsoever R., Hartkoorn E., Damen I., de Bethune M.P., et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 2003, 77(August (15)):8263-8271.
39. Roberts D.M., Nanda A., Havenga M.J., Abbink P., Lynch D.M., Ewald B.A., et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 2006, 441(May (7090)):239-243.
40. Bangari D.S., Mittal S.K. Current strategies and future directions for eluding adenoviral vector immunity. Curr Gene Ther 2006, 6(April (2)):215-226.